Search Legislation

Commission Decision of 28 July 2009 amending the list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products (notified under document C(2009) 5804) (Text with EEA relevance) (2010/28/EC)

 Help about what version

What Version

 Help about UK-EU Regulation

Legislation originating from the EU

When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.

Close

This item of legislation originated from the EU

Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).

Status:

This is the original version as it was originally adopted in the EU.
This legislation may since have been updated - see the latest available (revised) version

Commission Decision

of 28 July 2009

amending the list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products

(notified under document C(2009) 5804)

(Text with EEA relevance)

(2010/28/EC)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use(1), and in particular Article 16(f) thereof,

Having regard to the opinions of the European Medicines Agency, formulated on 10 January 2008 and 6 March 2008 by the Committee for Herbal Medicinal Products,

Whereas:

(1) Calendula officinalis L and Pimpinella anisum L comply with the requirements set out in Directive 2001/83/EC. Calendula officinalis L and Pimpinella anisum L can be considered as herbal substances, herbal preparations or combinations thereof.

(2) It is therefore appropriate to include Calendula officinalis L and Pimpinella anisum L in the list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products established in Annex I to Commission Decision 2008/911/EC(2).

(3) Decision 2008/911/EC should therefore be amended accordingly.

(4) The measures provided for in this Decision are in accordance with the opinion of the Standing Committee on Medicinal Products for Human Use,

HAS ADOPTED THIS DECISION:

Article 1

Decision 2008/911/EC is amended as follows:

1.

Annex I is amended in accordance with Annex I to this Decision.

2.

Annex II is amended in accordance with Annex II to this Decision.

Article 2

This Decision is addressed to the Member States.

Done at Brussels, 28 July 2009.

For the Commission

Günter Verheugen

Vice-President

ANNEX I

In Annex I to Decision 2008/911/EC, the following is inserted:

  • ‘Calendula officinalis L’ is inserted before Foeniculum vulgare Miller subsp. vulgare var. vulgare (Bitter fennel, fruit),

  • ‘Pimpinella anisum L’ is inserted after Foeniculum vulgare Miller subsp. vulgare var. dulce (Miller) Thellung (Sweet fennel, fruit).

ANNEX II

In Annex II to Decision 2008/911/EC, the following is inserted:

  • ‘Calendula officinalis L’ is inserted before Foeniculum vulgare Miller subsp. vulgare var. vulgare (Bitter fennel, fruit)

    COMMUNITY LIST ENTRY ON CALENDULA OFFICINALIS L

    Scientific name of the plant

    Calendula officinalis L.

    Botanical family

    Asteraceae

    Herbal substance

    Calendula flower

    Common name in all EU official languages of herbal substance

    • BG (bălgarski): Невен, цвят

    • CS (čeština): Měsíčkový květ

    • DA (dansk): Morgenfrueblomst

    • DE (Deutsch): Ringelblumenblüten

    • EL (elliniká): Άνθος καλέντουλας

    • EN (English): Calendula flower

    • ES (español): Flor de caléndula

    • ET (eesti keel): Saialilleõisik

    • FI (suomi): Tarhakehäkukan kukka

    • FR (français): Souci

    • HU (magyar): A körömvirág virága

    • IT (italiano): Calendula fiore

    • LT (lietuvių kalba): Medetkų žiedai

    • LV (latviešu valoda): Kliņģerītes ziedi

    • MT (malti): Fjura calendula

    • NL (nederlands): Goudsbloem

    • PL (polski): Kwiat nagietka

    • PT (português): Flor de calêndula

    • RO (română): Floare de gălbenele (calendula)

    • SK (slovenčina): Nechtíkový kvet

    • SL (slovenščina): Cvet vrtnega ognjiča

    • SV (svenska): Ringblomma, blomma

    • IS (íslenska): Morgunfrú, blóm

    • NO (norsk): Ringblomst

    Herbal preparation(s)

    A.Liquid extract (DER 1:1), extraction solvent ethanol 40-50 % (v/v).
    B.Liquid extract (DER 1:1,8-2,2), extraction solvent ethanol 40-50 % (v/v).
    C.Tincture (DER 1:5), extraction solvent ethanol 70-90 % (v/v).

    European Pharmacopoeia monograph reference

    Calendula flower – Calendulae flos (01/2005:1297)

    Indication(s)

    (a)Traditional herbal medicinal product for the symptomatic treatment of minor inflammations of the skin (such as sunburn) and as an aid in healing of minor wounds.
    (b)Traditional herbal medicinal product for the symptomatic treatment of minor inflammations in the mouth or the throat.

    The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use.

    Type of tradition

    European

    Specified strength

    Please see “Specified posology”.

    Specified posology

    Herbal preparations:

    A.

    Liquid extract (DER 1:1)

    In semi-solid dosage forms: amount equivalent to 2-10 % herbal substance.

    B.

    Liquid extract (DER 1:1,8-2,2)

    In semi-solid dosage forms: amount equivalent to 2-5 % herbal substance.

    C.

    Tincture (DER 1:5)

    In compresses diluted at least 1:3 with freshly boiled water.

    In semi-solid dosage forms: amount equivalent to 2-10 % herbal substance.

    As a gargle or mouth rinse in a 2 % solution.

    2 to 4 times daily

    Indication (a)

    The use is not recommended in children under 6 years of age (see below “Special warnings and precautions for use”).

    Indication (b)

    The use in children under 12 years of age is not recommended because there is no experience available (see below “Special warnings and precautions for use”).

    Route of administration

    Cutaneous and oromucosal use.

    Duration of use or any restrictions on the duration of use

    Compresses: remove after 30-60 minutes

    All herbal preparations: If the symptoms persist after 1 week during the use of the medicinal product a doctor or a qualified health care practitioner should be consulted.

    Any other information necessary for the safe use

    Contraindications

    Hypersensitivity to members of the Asteraceae (Compositae) family.

    Special warnings and precautions for use

    Indication (a)

    The use in children under 6 years of age is not recommended because there is no experience available.

    Indication (b)

    The use in children under 12 years of age is not recommended because there is no experience available.

    If signs of skin infection are observed, a doctor or a qualified health care practitioner should be consulted.

    Interactions with other medicinal products and other forms of interaction

    None reported.

    Pregnancy and lactation

    Safety during pregnancy and lactation has not been established.

    In the absence of sufficient data, the use during pregnancy and lactation is not recommended.

    Effects on ability to drive and use machines

    Not relevant.

    Undesirable effects

    Skin sensitisation. The frequency is not known.

    If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted.

    Overdose

    None reported.

  • ‘Pimpinella anisum L’ is inserted after Foeniculum vulgare Miller subsp. vulgare var. dulce (Miller) Thellung (Sweet fennel, fruit)

    COMMUNITY LIST ENTRY ON PIMPINELLA ANISUM L

    Scientific name of the plant

    Pimpinella anisum L.

    Botanical family

    Apiaceae

    Herbal substance

    Aniseed

    Common name in all EU official languages of herbal substance

    • BG (bălgarski): Анасон, плод

    • CS (čeština): Anýzový plod

    • DA (dansk): Anisfrø

    • DE (Deutsch): Anis

    • EL (elliniká): Γλυκάνισο

    • EN (English): Aniseed

    • ES (español): Fruto de anís

    • ET (eesti keel): Aniis

    • FI (suomi): Anis

    • FR (français): Anis (fruit d)

    • HU (magyar): Ánizsmag

    • IT (italiano): Anice (Anice verde), frutto

    • LT (lietuvių kalba): Anyžių sėklos

    • LV (latviešu valoda): Anīsa sēklas

    • MT (malti): Frotta tal-Anisi

    • NL (nederlands): Anijsvrucht

    • PL (polski): Owoc anyżu

    • PT (português): Anis

    • RO (română): Fruct de anason

    • SK (slovenčina): Anízový plod

    • SL (slovenščina): Plod vrtnega janeža

    • SV (svenska): Anis

    • IS (íslenska): Anís

    • NO (norsk): Anis

    Herbal preparation(s)

    Dried aniseed, comminuted or crushed

    European Pharmacopoeia monograph reference

    Anisi fructus (01/2005:0262)

    Indication(s)

    (a)Traditional herbal medicinal product for symptomatic treatment of mild, spasmodic gastro-intestinal complaints including bloating and flatulence.
    (b)Traditional herbal medicinal product used as an expectorant in cough associated with cold.

    The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use.

    Type of tradition

    European

    Specified strength

    Please see “Specified posology”

    Specified posology

    Adolescents over 12 years of age, adults, elderly:

    Indications (a) and (b)

    1 to 3,5 g of whole or (freshly(3)) comminuted or crushed aniseed in 150 ml of boiling water as a herbal tea

    3 times daily

    The use in children under 12 years is not recommended of age (see below “Special warnings and precautions for use”).

    Route of administration

    Oral use

    Duration of use or any restrictions on the duration of use

    Not to be taken for more than 2 weeks.

    If the symptoms persist during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.

    Any other information necessary for the safe use

    Contraindications

    Hypersensitivity to the active substance or to Apiaceae (Umbelliferae) (caraway, celery, coriander, dill and fennel) or to anethole.

    Special warnings and precautions for use

    The use is not recommended in children under 12 years of age due to the lack of adequate data for safety assessment.

    Interactions with other medicinal products and other forms of interaction

    None reported.

    Pregnancy and lactation

    There are no data from the use of aniseed in pregnant patients.

    It is unknown if aniseed constituents are excreted in human breast milk.

    In the absence of sufficient data, the use during pregnancy and lactation is not recommended.

    Effects on ability to drive and use machines

    No studies on the effect on the ability to drive and use machines have been performed.

    Undesirable effects

    Allergic reactions to aniseed affecting the skin or the respiratory system may occur. The frequency is not known.

    If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted.

    Overdose

    No case of overdose has been reported.

(3)

For commercial preparations of comminuted or crushed aniseed the applicant must carry out appropriate stability testing related to the content of essential oil components.’

Back to top

Options/Help

Print Options

Close

Legislation is available in different versions:

Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.

Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.

Close

Opening Options

Different options to open legislation in order to view more content on screen at once

Close

More Resources

Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as adopted version that was used for the EU Official Journal
  • lists of changes made by and/or affecting this legislation item
  • all formats of all associated documents
  • correction slips
  • links to related legislation and further information resources
Close

More Resources

Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as adopted version that was used for the print copy
  • correction slips

Click 'View More' or select 'More Resources' tab for additional information including:

  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • links to related legislation and further information resources